12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VS-6063: Additional Phase I data

Additional data from 6 patients with advanced ovarian cancer in the dose-escalation Phase I portion of an open-label, U.S. Phase I/Ib trial showed that twice-daily oral VS-6063 plus IV paclitaxel led to 1 confirmed complete response as measured by RECIST criteria. Last month, Verastem reported data from the Phase I portion showing that...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >